WOOD BARBARA A
Known title: EVP, Gen. Counsel, Corp. Sec.CIK: 0001220051
Associated companies
Transaction History
| SLS | ▲ Buy | Grant | 35,000 | $0 | 1/22/2024 | View on chart |
| SLS | ▼ Sell | Other | 4,119 | $4K | 12/6/2023 | View on chart |
| SLS | ▲ Buy | Grant | 20,000 | $0 | 2/2/2023 | View on chart |
| SLS | ▼ Sell | Open Market | 2,153 | $6K | 12/5/2022 | View on chart |
| SLS | ▲ Buy | Grant | 13,000 | $0 | 1/31/2022 | View on chart |
| SLS | ▼ Sell | Open Market | 847 | $5K | 12/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
SLS Stock Fluctuates Amid M&A Speculation and New AML Study
SELLAS Life Sciences shares have seen volatile movement driven by retail investor speculation about potential M&A activity at the ASH conference. Recent news also highlights a new AML study that has fueled optimism among some investors regarding the company's pipeline. While the stock has experienced a recent rally, momentum has slowed, leaving it trading well below the average analyst target price.
SLS Stock Fluctuates Amid M&A Speculation and New AML Study. SELLAS Life Sciences shares have seen volatile movement driven by retail investor speculation about potential M&A activity at the ASH conference. Recent news also highlights a new AML study that has fueled optimism among some investors regarding the company's pipeline. While the stock has experienced a recent rally, momentum has slowed, leaving it trading well below the average analyst target price.